Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis

Clinical Infectious Diseases

Volumn 48, Issue 10, 2009, Pages 1354-1360

  Long, Richard ^a,f   Chong, Huey ^c   Hoeppner, Vernon ^d   Shanmuganathan, Hareishun ^e   Kowalewska Grochowska, Kinga ^b   Shandro, Cary ^b   Manfreda, Jure ^e   Senthilselvan, Ambikaipakan ^b   Elzainy, Abeer ^a   Marrie, Thomas ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Capital Health Edmonton   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f ALBERTA HOSPITAL EDMONTON   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CANADA; CASE CONTROL STUDY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG USE; EMPIRICISM; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; COMMUNICABLE DISEASE; DRUG EFFECT; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBERTA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENTS; PNEUMONIA; SASKATCHEWAN; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 65549120186     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598196     Document Type: Article

References (35)

1. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2005;3:CD004795.
2. Moadebi S, Harder CK, FitzGerald MJ, Elwood KR, Marra F. Fluo- roquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-99.
3. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6.
4. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38.
5. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
6. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002;34: 1607-12.
7. Yoon YS, Lee HJ, Yoon HI, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005;9:1215-19.
8. Wang J-Y, Hsueh P-R, Jan I-S, et al. Empiric treatment with a fluo- roquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61:903-8.
9. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-2.
10. Costello HD, Caras GJ, Snider DE Jr. Drug resistance among previously treated tuberculosis patients, a brief report. Am Rev Respir Dis 1980;121:313-6.
11. IMS Health. Available at: http://www.imshealth.com/portal/site/imshealth. Accessed 26 March 2009.
12. Chen C-H, Shih J-F, Lindholm-Levy PJ, Heifets LB. Minimal inhibitory concentrations of rifabutin, ciprofloxacin, ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis 1989;140:987-9.
13. Pfyffer GE, Bonato DA, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the ra- diometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999;37:3179-86.
14. Perlman DC, El Sadr WM, Heifets LB, et al. Susceptibility to levo-floxacin of Mycobacterium tuberculosis isolates from patients with HIV- related tuberculosis and characterization of a strain with levofloxacin resistance. AIDS 1997;11:1473-8.
15. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocariae, and other aerobic actinomycetes. Approved standard M24-A, vol. 23, no. 18. Wayne, PA: CLSI, 2003:10-9, 33-5, 65.
16. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006;50:104-12.
17. Giannoni F, Iona E, Sementilli F, et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:2928-33.
18. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773- 80.
19. Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoro-quinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007;167:2317-23.
20. Perez-Guzman C, Vargas MH, Torres-Cruz A, Villarreal-Velarde H. Does aging modify pulmonary tuberculosis? A meta-analytical review. Chest 1999;116:961-7.
21. Liam C-K, Pang Y-K, Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology 2006;11:786-92.
22. Wang J-Y, Lee L-N, Lai H-C, et al. Fluoroquinolone resistance in My- cobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007;59:860-5.
23. Park I-N, Hong S-B, Oh Y-M, et al. Impact of short term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007;11:319-24.
24. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448- 52.
25. Ruiz-Serrano MJ, Alcala L, Martinez L, et al. In vitro activity of six fluorquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line anti-tuberculosis drugs. An-timicrob Agents Chemother 2000;44:2567-8.
26. Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen in a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001;5:546-50.
27. Huang TS, Kunin CM, Lee SSJ, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicob Chemother 2005;56:1058- 62.
28. Bozeman L, Burman W, Metchock B, Welch L, Weiner M; Tuberculosis Trials Consortium. Fluoroquinolone susceptibility among Mycobacte- rium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005;40:386-91.
29. Riantawan P, Punnotok J, Chaisuksuwan R, Pransujarit V. Resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in the central region of Thailand, 1996. Int J Tuberc Lung Dis 1998;2:616-20.
30. Casal M, Ruiz, Herreras A. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance. Int J Tuberc Lung Dis 2000;4:588-91.
31. Umubyeyi AN, Rigouts L, Shamputa IC, et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007;59:1031-3.
32. Ginsburg AS, Woolwine S, Hooper AS, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. New Engl J Med 2003;349:1977-8.
33. Long R, Zielinski M, Kunimoto D, Manfreda J. The emergency department is a determinant point of contact of tuberculosis patients prior to diagnosis. Int J Tuberc Lung Dis 2002;6:332-9.
34. Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO. Fluoroquinolone utilization in the emergency departments of academic medical centers. Arch Intern Med 2003;163:601-5.
35. Sterling TR. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 2004;8:1396-400.